pdf   xlsx method abbreviations

la/mBC - HR-positive - 2nd line (L2), phosphoinositide 3-kinase (PI3K) inhibitor , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.87 [0.75, 1.00]< 10%2 studies (2/-)97.6 %lownot evaluable highcrucial-
progression or deaths (PFS) 0.76 [0.67, 0.85]< 10%3 studies (3/-)100.0 %lownot evaluable highimportant-
CBR 1.93 [1.25, 2.97]> 10%1 study (1/-)99.9 %NAnot evaluable non important-
objective responses (ORR) 1.90 [1.25, 2.88]> 134%2 studies (2/-)99.9 %lownot evaluable highnon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.